Ali Tehrani

Ali Tehrani is an accomplished professional in the biotech industry, currently serving as a Partner and Venture Partner at Amplitude Ventures since March 2022. As a Co-Founder of DCx Biotherapeutics Corporation and a Board Member at both Reverb Therapeutics, where innovative Amplifier technology is utilized for therapeutic applications, and QurCan Therapeutics Inc., Ali contributes significant expertise to multiple organizations. Previous experience includes serving as Board Member at Creatus Biosciences Inc. from 2015 to 2023 and leading Zymeworks as Co-founder, President, and CEO from its inception in 2003 until January 2022. Ali holds a PhD in Microbiology and Immunology from The University of British Columbia, as well as an M.S. in Biochemistry and a Bachelor of Applied Science in Biochemistry from the University of Massachusetts Amherst.